Predicting disease progression in patients with viable: Tumor at post-chemotherapy RPLND

被引：0
|
作者：
Spiess, Philippe E.
Brown, Gordon A.
Tannir, Nizar M.
Tu, Shi-Ming
Liu, Ping
Kamat, Ashish M.
Wood, Christopher G.
Evans, James G.
Pisters, Louis L.
机构：
来源：
JOURNAL OF UROLOGY | 2007年 / 177卷 / 04期
关键词：
D O I：
10.1016/S0022-5347(18)31074-7
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：278 / 278
页数：1
相关论文
共 50 条
  • [1] Post-chemotherapy RPLND for testis cancer
    Horenblas, S.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S78 - S79
  • [2] SERUM MIRNA PREDICTS VIABLE DISEASE POST-CHEMOTHERAPY IN TESTICULAR NON-SEMINOMA GERM CELL TUMOR PATIENTS
    Leao, Ricardo
    van Agthoven, Ton
    Fadaak, Kamel
    Castelo-Branco, Pedro
    Jewett, Michael
    Sweet, Joan
    Ahmad, Ardalan E.
    Anson-Cartwright, Lynn
    Chung, Peter
    Hansen, Aaron
    Warde, Padraig
    O'Malley, Martin
    Bedard, Philippe L.
    Looijenga, Leendert H. J.
    Hamilton, Robert J.
    JOURNAL OF UROLOGY, 2018, 199 (04): : E494 - E494
  • [3] Is percent seminoma associated with intraoperative morbidity during post-chemotherapy RPLND?
    Russell, Christopher M.
    Sharma, Pranav
    Agarwal, Gautum
    Fisher, John S.
    Richard, George J.
    Spiess, Philippe E.
    Pow-Sang, Julio M.
    Poch, Michael A.
    Sexton, Wade J.
    CANADIAN JOURNAL OF UROLOGY, 2016, 23 (01) : 8127 - 8134
  • [4] IS PERCENT SEMINOMA ASSOCIATED WITH INTRAOPERATIVE MORBIDITY DURING POST-CHEMOTHERAPY RPLND?
    Sharma, Pranav
    Zargar-Shoshtari, Kamran
    Poch, Michael
    Powsang, Julio
    Sexton, Wade
    Spiess, Philippe
    Gilbert, Scott
    JOURNAL OF UROLOGY, 2016, 195 (04): : E839 - E839
  • [5] Serum miRNA to predict post-chemotherapy viable disease in testicular non-seminomatous germ cell tumor patients.
    Leao, Ricardo Romao Nazario
    Van Agthoven, Ton
    Figueiredo, Arnaldo
    Fadaak, Kamel
    Castelo-Branco, Pedro
    Jewett, Michael A. S.
    Sweet, Joan
    Ahmad, Ardalan
    Anson-Cartwright, Lynn
    Bedard, Philippe L.
    Chung, Peter W. M.
    Hansen, Aaron Richard
    Warde, Padraig Richard
    O'Malley, Martin
    Looijenga, Leendert
    Hamilton, Robert James
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [6] Outcomes of post-chemotherapy retroperitoneal lymph node dissection (RPLND) in testicular cancers
    Iang, H. G. Y.
    Sim, H. G.
    Cheng, C. W. S.
    Lee, L. S.
    BJU INTERNATIONAL, 2015, 115 : 25 - 27
  • [7] Post-chemotherapy residual tumor resection in patients with elevated tumor markers
    Che, Y.
    Winter, C.
    Siemer, Grosse R.
    Hiester, A.
    Albers, P.
    EUROPEAN UROLOGY, 2021, 79 : S910 - S910
  • [8] Sarcopenia prior to and following chemotherapy to predict morbidity in patients undergoing post-chemotherapy retroperitoneal lymphadenectomy (PC-RPLND).
    Baky, Fadya
    Woldu, Solomon L.
    Margulis, Vitaly
    Bagrodia, Aditya
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [9] Post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) for advanced nonseminomatous germ cell tumor (NSGCT): Correlation of teratoma in the primary tumor and RPLND histology
    Callegaro Filho, Donato
    Smaletz, Oren
    Mutao, Taciana Sousa
    Maia Loureiro, Luiz Victor
    Silvestro e Silva Macarenco, Ricardo
    Rosenblatt, Charles
    Alter, Wladimir, Jr.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [10] PRIMARY VERSUS POST-CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION (RPLND) IN PATIENTS WITH PRESENCE OF TERATOMA AT ORCHIECTOMY
    Williams, Stephen
    Kacker, Ravi
    Steele, Graeme
    Richie, Jerome
    JOURNAL OF UROLOGY, 2010, 183 (04): : E221 - E221
12345